**BACKGROUND**

Cyclin-dependent kinase (CDK) inhibitors combined with endocrine therapy offer an important new treatment approach to hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. This study determined whether online continuing medical education could improve oncologists' and obstetricians/gynecologists' knowledge of the use of CDK4/6 inhibitors in practice, competence in treatment selection, and confidence in management of side effects.

**METHODS**

Each individual tracked pre and posteducation. A validated online video roundtable discussion among 3 experts was launched for countries outside the United States in January 2017, with data collected until March 2017.

**RESULTS**

**QUESTION 1 RESULTS**

Significant improvement by oncologists in identification of fulvestrant benefit in patients without visceral metastases: Table 1. Each question was answered by oncologists (n = 101) and obstetricians and gynecologists (n = 31) in the baseline phase and the intervention phase with the help of online medical education. Significant improvement in identification of fulvestrant benefit in patients without visceral metastases. (Correct answer: Palbociclib in combination with fulvestrant)

**QUESTION 2 RESULTS**

Significant improvement in correct selection of second-line CDK4/6 inhibitors + fulvestrant: Table 2. Each question was answered by oncologists (n = 101) and obstetricians and gynecologists (n = 31) in the baseline phase and the intervention phase with the help of online medical education. Significant improvement by oncologists in correct selection of second-line CDK4/6 inhibitors + fulvestrant: (Correct answer: Based on the PALOMA-2 and MONALEESA-2 trials, almost all patients benefit from CDK4/6 inhibitors in combination with hormonal therapy, as noted by significant increases in PFS compared with hormonal therapy alone)

**QUESTION 3 RESULTS**

High baseline understanding of patients eligible for CDK4/6 inhibitors: Table 3. Each question was answered by oncologists (n = 101) and obstetricians and gynecologists (n = 31) in the baseline phase and the intervention phase with the help of online medical education. High baseline understanding of patients eligible for CDK4/6 inhibitors: (Correct answer: Based on the FALCON trial subgroup analysis of patients without visceral metastases, significant improvement by oncologists in identification of fulvestrant benefit in patients without visceral metastases)

**SELF-EFFICACY RESULTS**

Very confident in identification of fulvestrant benefit in patients without visceral metastases: Table 4. Each question was answered by oncologists (n = 101) and obstetricians and gynecologists (n = 31) in the baseline phase and the intervention phase with the help of online medical education. Very confident in identification of fulvestrant benefit in patients without visceral metastases (Correct answer: Palbociclib in combination with fulvestrant)

**CONCLUSION**

This on-demand, online video roundtable discussion resulted in significant, positive educational effect.Baseline findings indicate that both specialties, but in particular obstetricians/gynecologists, would benefit from further education to facilitate optimal application of CDK4/6 inhibitors in practice.

Online medical education is valuable in supporting introduction of new therapies, as well as identifying areas of continued educational need.

**ACKNOWLEDGMENTS**

The educational activity and outcomes measurement were funded through an independent educational development fund. For more information, contact Javier Negron, PhD, Global Clinical Strategy, Medscape Education, jnegron@medscape.net.

G. FISHER, Medscape, Global Education, London, United Kingdom; D. MIDDLETON, Medscape, Global Education, New York, USA; C. DAY, Medscape, Global Education, London, United Kingdom; N. HARBECK, University of Munich, Department of Obstetrics and Gynecology, Munich, Germany.

---

**IMAGE**

Two analyses of the pre/post sample.